AAIC 2017: Pipeline analysis reveals that 35 Alzheimer’s drugs are in Phase II and III clinical development

Written by Jonathan Wilkinson

A pipeline analysis presented at the Alzheimer’s Association International Conference (AAIC 2017, 16–20 July, London, UK) has revealed that 27 Alzheimer’s drugs in Phase III clinical trials and eight drugs in Phase II clinical trials may be on the market within the next 5 years.  The analysis was reported by ResearchersAgainstAlzheimer’s (RA2), a network of UsAgainstAlzheimer’s. George Vradenburg, co-Founder and Chairman of UsAgainstAlzheimer’s, explained: “The Alzheimer’s disease pipeline, marred by decades of failures and underinvestment, is due for big victories. Thanks to growing investment from industry leaders, we remain cautiously optimistic that the current crop of late-stage Alzheimer’s innovations will...

To view this content, please register now for access

It's completely free